Cefixime: An Oral Option for the Treatment of Multidrug-Resistant Enteric Fever in Children

Select Content Type
Resources
Authored By
Shalina MedSpace
Authored On
Interests
Cardiology
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pediatric Medicine
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Speciality
Cardiology
Dentistry
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Geriatrics
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Medical Genetics
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pathology
Pediatric Medicine
Pharmacology
Psychiatry
Public Health
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Thumbnail Image
Cefixime MDR_thumbnail
Detail Image
Cefixime MDR_mobile image
Book Detail
Actions
Download in App
Countries of release
India
Nigeria
UAE
IS_Ebsco
false
Description

Cefixime has emerged as a valuable oral treatment option for managing multi-drug-resistant (MDR) enteric fever in children. Clinical findings from a study conducted among 85 patients with enteric fever indicate that cefixime provides effective therapy with good tolerance, making it a practical alternative to parenteral agents. 

Its oral administration not only improves compliance and comfort for pediatric patients but also reduces the need for hospitalization and the costs associated with intravenous therapy. 

As antimicrobial resistance continues to rise, cefixime represents an important tool in expanding treatment options for MDR enteric fever.

Published Date